Table 1.

Recent clinical trials related to TCR-T cells for the treatment of HCC.

Clinical Trial	NCT number	Host/Country
Redirected HBV-specific T Cells in patients with HBV-related HCC (SAFE-T-HBV) (SAFE-T-HBV)	NCT04745403	Singapore General Hospital, Singapore
TCR-redirected T cell infusion in subjects with recurrent HBV-related HCC post liver transplantation	NCT02719782	The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
TCR-redirected T cell treatment in patients with recurrent HBV-related HCC post liver transplantation	NCT04677088	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
TCR-redirected T cell infusions to prevent HCC recurrence post Liver transplantation	NCT02686372	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Autologous CAR-T/TCR-T cell immunotherapy for solid malignancies	NCT03941626	Henan Provincial People’s Hospital, Zhengzhou, Henan, China
Autologous CAR-T/TCR-T cell immunotherapy for malignancies	NCT03638206	The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

HBV, Hepatitis B Virus; HCC, Hepatocellular Carcinoma; TCR, T Cell Receptor; CAR-T, Chimeric Antigen Receptor T-Cell; TCR-T, T cell receptor T-Cells.